

SMi's 2nd Annual Highly Potent Active Pharmaceutical Ingredients Conference – Under A Week Left!

Discover the balance between safety, quality and cost-effectiveness by addressing containment and cross-contamination issues

LONDON, UNITED KINGDOM, May 16, 2018 /EINPresswire.com/ -- Discover the balance between safety, quality and cost-effectiveness by addressing containment and cross-contamination issues

16 Exhilarating Presentations | 8+ Hours of Networking | 18 Hours of Interactive Content | 2 Hands on Workshop

An Audience of Highly Potent API Experts & Innovators Under 1 Roof

With the event now under 1 week away, this is a reminder there is still time to register at SMi's 2nd annual, Highly Potent Active Pharmaceutical Ingredients conference, taking place between May 21st - 23rd, Kensington, London UK.



The highly anticipated 3-day conference will gather the growing hpapi community, filled with industry thought leaders and drug development experts involved in: cross contamination, manufacturing, containment design, liquid and parentals, R&D and pharmaceutical process development.

“

Look at ADCs, highly potent APIs that previously were too toxic (including too narrow a therapeutic window) have been reborn when used in a much lower but highly targeted manner.”

Justin Mason-Home, Director, HPAPI Project Services

Highlights to look forward to:

- Discover practical approaches to HPAPI manufacturing in a controlled and efficient manner
- Explore different containment methods and learn about which strategy best suits your needs
- Evaluate the use of containment risk mitigation tools in early phase development

- Learn how to manage and effectively and safely dispose of HPAPI, post-production waste
- Discuss the most important regulations surrounding potent ingredients

Where Innovation starts, Pioneers meet, and Collaborations begin!

Take advantage of meeting peers under one roof with over 8 hours of networking. Visit the download centre online to take a look at the full attendee list and access exclusive content from our key speakers, including one to one interviews.

Snap shot of those confirmed include:

Co-Owner and Director | Dep. Head of Drug Substance Development Division | Developing chemical Engineer | Director and Regulatory Manager Pharmaceuticals | Director Global EHS Technical Operations | Director of Containment & Micronisation | Head of Launch Preparation and Coordination | Head of Manufacturing | President / CEO | Principle Scientist | Principal Scientific Manager, Small Molecule Process Chemistry | Senior Formulation Scientist | Senior Scientific Advisor

There is currently a [manager'sspecial](#) rate available online. Book today: www.highlypotentapi.com/ein

SMi presents the 2nd Annual:

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

Date: 21st – 22nd May 2018

Workshops: 23rd May 2018

Location: Holiday Inn Kensington Forum, London UK

[Website: http://www.highlypotentapi.com/ein](http://www.highlypotentapi.com/ein)

---end---

Contact Information:

For all media inquiries contact Pav Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Pav Solanki
SMi Group
2078276048
[email us here](mailto:psolanki@smi-online.co.uk)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.